Search

Insert abstract text here. 10H-Dibenzo[b,e][1,4]thiaborinine 5,5-dioxide (SO2B) - a new high triplet (T1 = 3.05 eV) strongly electron-accepting boracycle - was successfully utilised in TADF emitters PXZ-Dipp-SO2B and CZ-Dipp-SO2B. We demonstrate the near complete separation of HOMO and LUMO leading to a low oscillator strength of the S1→S0 CT transition, resulting in very long ca. 83 ns and 400 ns prompt fluorescence lifetime for CZ-Dipp-SO2B and PXZ-Dipp-SO2B respectively, but retaining near unity photoluminescence quantum yield. Devices based on CZ-Dipp-SO2B have high EQE = 23.3% and maximum luminance of 18600 cd m-2 with low efficiency roll off at high brightness. For CZ-Dipp-SO2B rISC is mediated through the vibronic coupling of two CT states, without involving the 3LE, resulting in remarkable rISC rate invariance to environmental polarity and polarizability whilst giving near 100% IQE. This new form of rISC allows stable OLED performance to be achieved in different host environments.

Chromatography (TLC and HPLC) tests were performed of 11 preparations containing dry extract of Ginkgo biloba leaves: three pharmaceuticals (preparations 1, 3 and 5) and eight dietary supplements (preparations 2, 4, 6-11), and dry extract of Ginkgo biloba leaves (preparation 12) as a standard certified for compliance with Eur. Ph. 6.1. and FP VIII (1, 2). Preparations registered in Poland as pharmaceuticals contained the major active ingredients (flavonoids and terpene lactones) in amount declared by their producers (and consistent with pharmacopoeial requirements) and acceptable level of potentially toxic ginkgolic acids (below 5 ppm). The concentration of active compounds in dietary supplements was varied. Some of them satisfied applicable quality criteria (mainly preparation 8), however, the majority had reduced levels of therapeutic compounds (4, 6, 7, 11) and increased concentration of ginkgolic acids (4, 9, 10, 11).

Introduction: Recent reports have suggested an association between genetic polymorphisms of dopamine receptors and the development of an increased risk of chronic hypertension, as well as preeclampsia (PE). Objectives: The aim of the study was to evaluate the impact of the -48A>G DRD1 and -521C>T DRD4 polymorphisms in the etiology of PE among Polish women. Material and methods: Ninety-eight preeclamptic women and 120 healthy pregnant controls were enrolled in the study. The investigated polymorphisms of the DRD1 and DRD4 genes were identified using PCR/RFLP methods. Results: As far as the -48A>G DRD1 polymorphism is concerned, the mutated -48GG genotype was more often found in controls (14.2% ) than in the PE group (10.2%, ns), and the subgroup with severe PE (8.2%). Also, the frequency of the mutated -48G allele was higher in controls (39.6%) than in the PE group (33.2%, ns), and in the subgroup with severe PE (31.6%, ns). As for the -521C>T DRD4 polymorphism, a similar occurrence of the mutated -521TT genotype and the -521T allele in all of the investigate groups was observed. Lower serum concentrations of total protein (5.59 g/L and 5.57 g/L vs. 6.17 g/L in carriers of the -521CC genotype, p=0.02) were noted in patients with the mutated homozygous -521TT genotype and heterozygous -521CT genotype of DRD4. Conclusions: The obtained results suggest a possible protective role of the mutated -48G DRD1 allele in the etiology of preeclampsia, especially its severe form. The presence of the mutated -521T DRD4 allele could influence the decrease of total blood protein in preeclamptic patients. The observed frequency of dopamine DRD1 and DRD4 polymorphisms is similar to the distribution of these variants in other Caucasian populations.